ストックスクリーナーアプリを入手
5.31
0.95%
0.05
Taysha Gene Therapies Inc (TSHA) 最新ニュース
Chardan Capital Maintains Buy Rating on TSHA at $12 | TSHA Stock News - GuruFocus
Raymond James reiterates Strong Buy on Taysha Gene Therapies stock By Investing.com - Investing.com Canada
Taysha doses first patient in pivotal Rett syndrome gene therapy trial - Investing.com Australia
Taysha Gene Therapies (TSHA) Advances in Rett Syndrome Gene Ther - GuruFocus
Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome - The Manila Times
New gene therapy trial progresses for children and adults with Rett syndrome - Stock Titan
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Cut to "Sell" at Wall Street Zen - MarketBeat
Aug Highlights: Can Taysha Gene Therapies Inc stock rebound after recent weaknessIPO Watch & Precise Buy Zone Tips - moha.gov.vn
Taysha Gene Therapies (NASDAQ:TSHA) Shares Down 4.8%What's Next? - MarketBeat
Rice Hall James & Associates LLC Buys New Holdings in Taysha Gene Therapies, Inc. $TSHA - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap UpHere's Why - MarketBeat
Taysha Gene Therapies stock hits 52-week high at $5.98 By Investing.com - Investing.com Nigeria
Taysha Gene Therapies stock hits 52-week high at $5.98 - Investing.com
Taysha Gene Therapies (NASDAQ:TSHA) Reaches New 1-Year HighHere's What Happened - MarketBeat
Does Taysha Gene Therapies Still Offer Value After a 196.8% Year to Date Surge? - Yahoo Finance
Is FDA Breakthrough Status For TSHA-102 Reshaping The Investment Case For Taysha Gene Therapies (TSHA)? - Yahoo Finance
Taysha Gene Therapies (TSHA): Revisiting Valuation After Breakthrough Rett Data and Bullish Analyst Upgrades - Yahoo Finance
Taysha Gene (TSHA) Hovers Around Its 52-Week High As It Continues to Advance Rett Syndrome Program - Insider Monkey
Is Taysha Gene Therapies Inc. stock recession proofQuarterly Portfolio Report & Free Technical Confirmation Trade Alerts - Улправда
How analysts rate Taysha Gene Therapies Inc. stock todayBull Run & Weekly Stock Breakout Alerts - Улправда
Earnings Report: Is Taysha Gene Therapies Inc. stock recession proofWeekly Stock Analysis & Risk Controlled Stock Alerts - Улправда
Breakouts Watch: Is Taysha Gene Therapies Inc. stock recession proof2025 Trade Ideas & Free Fast Gain Swing Trade Alerts - Улправда
Can Taysha Gene Therapies Inc. stock beat analyst upgradesPortfolio Performance Summary & Growth Focused Stock Pick Reports - DonanımHaber
Can Taysha Gene Therapies Inc. stock rebound after recent weaknessQuarterly Trade Summary & Free Growth Oriented Trading Recommendations - DonanımHaber
Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock By Investing.com - Investing.com Canada
Taysha Gene Therapies (NASDAQ:TSHA) Hits New 1-Year HighTime to Buy? - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Rating Increased to Hold at Wall Street Zen - MarketBeat
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
1,203,941 Shares in Taysha Gene Therapies, Inc. $TSHA Purchased by Stempoint Capital LP - MarketBeat
B Group Inc. Buys 545,000 Shares of Taysha Gene Therapies, Inc. $TSHA - MarketBeat
Taysha Gene Therapies stock hits 52-week high at 5.51 USD - Investing.com
Taysha Gene Therapies stock hits 52-week high at 5.51 USD By Investing.com - Investing.com South Africa
200,000 Shares in Taysha Gene Therapies, Inc. $TSHA Bought by Affinity Asset Advisors LLC - MarketBeat
Taysha Gene Therapies Grants Stock Options to New Employees as Part of Inducement Plan - Quiver Quantitative
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Can Taysha Gene Therapies Stock Hold Up When Markets Turn? - Trefis
Taysha Gene Therapies upgraded at Goldman Sachs on advancing Rett syndrome asset - MSN
Would You Still Hold Taysha Gene Therapies Stock If It Fell 30%? - Trefis
Taysha Gene Therapies (TSHA) Upgraded to Buy by Goldman Sachs - GuruFocus
Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 7%Still a Buy? - MarketBeat
Taysha Gene Therapies (TSHA) Receives Buy Rating from Goldman Sa - GuruFocus
Taysha Gene Therapies (NASDAQ:TSHA) Shares Down 6.5% on Insider Selling - MarketBeat
How Taysha Gene Therapies Inc. stock reacts to oil prices2025 EndofYear Setup & Technical Confirmation Alerts - Newser
Sukumar Nagendran Sells 110,125 Shares of Taysha Gene Therapies (NASDAQ:TSHA) Stock - MarketBeat
Taysha Gene Therapies Insider Sold Shares Worth $1,695,906, According to a Recent SEC Filing - marketscreener.com
28.63%
大文字化:
|
ボリューム (24 時間):